Verastem (VSTM) Cash from Financing Activities (2011 - 2026)
Verastem's (VSTM) quarterly Cash from Financing Activities came in at $28.7 million in Q1 2026, down 57.45% year-on-year from $67.4 million in Q1 2025, and down 70.9% quarter-over-quarter from $98.6 million in Q4 2025.
Verastem (VSTM) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Verastem's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 57.45% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $224.6 million, a 85.04% increase from a year earlier, with the FY2025 full-year figure at $263.3 million, up 380.64% from the prior year.
- Cash from Financing Activities eased to $28.7 million in Q1 2026 per VSTM's latest filing, from $98.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $98.6 million in Q4 2025 and bottomed at -$891000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $25.5 million (2022), against an average of $33.3 million.
- Across the five-year window, Cash from Financing Activities slumped 103.48% in 2023 and jumped 19708.89% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $25.6 million in 2022, then slumped by 101.74% to -$446000.0 in 2023, then surged by 266.37% to $742000.0 in 2024, then soared by 13186.12% to $98.6 million in 2025, then plunged by 70.9% to $28.7 million in 2026.
- Per Business Quant, the three latest VSTM Cash from Financing Activities figures stand at $28.7 million (Q1 2026), $98.6 million (Q4 2025), and $17.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | 28.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.69 Mn |
| Mar 31, 2026 | 28.69 Mn |
| Dec 31, 2025 | 98.58 Mn |
| Dec 31, 2025 | 98.58 Mn |
| Sep 30, 2025 | 17.88 Mn |
| Sep 30, 2025 | 17.88 Mn |
| Jun 30, 2025 | 79.42 Mn |
| Jun 30, 2025 | 79.42 Mn |
| Mar 31, 2025 | 67.43 Mn |
| Mar 31, 2025 | 67.43 Mn |
| Dec 31, 2024 | 742,000.00 |
| Dec 31, 2024 | 742,000.00 |
| Sep 30, 2024 | 53.60 Mn |
| Sep 30, 2024 | 53.60 Mn |
| Jun 30, 2024 | -405,000.00 |
| Jun 30, 2024 | -405,000.00 |
| Mar 31, 2024 | 846,000.00 |
| Mar 31, 2024 | 846,000.00 |
| Dec 31, 2023 | -446,000.00 |
| Dec 31, 2023 | -446,000.00 |